Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Biotech’s Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

BY | ETF Database
10/12/2026 | 22 VIEWS
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines.Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs. Institutional capital and leveraged funds are surging while retail investors remain deeply cautious. Performance varies heavily depending on whether funds focus on equal-weight small caps or mega-cap leaders. One fund that has been benefiting significantly from the broader biotech sector’s rebound and heavy mergers and acquisitions activity is the Direxion Daily S&P Biotech Bull 3x Shares (LABU C+). While its reference index has been down for the past week, LABU has pulled in $266 million over that same period. The fund has also been up 52.5% year to date and has surged about 118% over the past 12 months. LABU, which has a 0.96% expense ratio, tracks the S&P Biotechnology Select Industry Index (SPSIBITR) and is designed to deliver triple the daily performance of said index. See More: Top Performing Leveraged/Inverse ETFs: 10/04/2026Uptick in Pharmaceutical M&A’sThe main driver of the potential market upswing in the biotech sector is a massive surge in mergers and acquisitions in the pharmaceutical space, with drugmakers announcing 37 biotech company purchases worth at least $1 billion each this year so far, according to Stocktwits. Total transaction value has reached $216 billion in 2026, nearly doubling from $118 billion the previous year. These purchases are expected to replace revenue loss that will come from impending patent expirations. Morningstar estimated that patent expirations could create a $139 billion revenue headwind for the largest biopharma companies through 2030. Consequently, large drugmakers are opting to acquire companies with late-stage or commercially ready pipelines rather than absorbing years of clinical risk through internal development. These deals include Vertex Pharmaceuticals (VRTX) agreeing to acquire Crinetics Pharmaceuticals (CRNX) for $10 billion, AbbVie (ABBV) making a deal to buy Apogee Therapeutics’ (APGE) late-stage immunology pipeline for $10.9 billion, and GSK (GSK) paying $10.6 billion for Nuvalent (NUVL).Retail SentimentEven with the all the renewed interest in biotech stocks, retail investors’ feelings around them have mirrored the broader sector’s cautious tone. According to Stocktwits, retail confidence in the State Street SPDR S&P Biotech ETF (XBI A) dropped to a record-low score of 21 out of 100. The ticker’s watcher has gone up a modest 4% over the past year. As a result of retail investors showing record-low confidence in baseline biotech ETFs like the XBI fund, due to fears of a top or high volatility, leveraged instruments like LABU frequently see sharp shifts between speculative bullish trading dips and deep bearish caution. Ultimately, whether biotech becomes the next true breakout trade depends on bridging the sentiment gap between Wall Street and Main Street. The glaring contrast between record-breaking institutional dealmaking and extreme retail pessimism creates an interesting crossroads for the market. For more news, information, and analysis, visit the Leveraged & Inverse Content Hub.

More Commentary

SpaceX AI Chip Spending Could Make 1 of These ETFs Blast Off
BY | ETF Database
10/12/2026 | 43 VIEWS
4Q26 Defense Sector Guide - Opportunities Amid Instability
BY | ETF Database
10/12/2026 | 47 VIEWS
Brian Hartigan on Why Invesco's QQQ Suite Stands Out Among Competitors
BY | ETF Database
10/12/2026 | 49 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.